Calidi Biotherapeutics (NYSE:CLDI – Get Free Report) posted its earnings results on Tuesday. The company reported ($1.40) earnings per share for the quarter, beating the consensus estimate of ($1.43) by $0.03, Yahoo Finance reports.
Calidi Biotherapeutics Price Performance
CLDI stock traded down $0.02 during midday trading on Wednesday, reaching $1.63. 18,825 shares of the company were exchanged, compared to its average volume of 155,339. Calidi Biotherapeutics has a 1-year low of $1.41 and a 1-year high of $137.90.
Analyst Ratings Changes
Several equities analysts have commented on CLDI shares. Robert W. Baird decreased their price target on shares of Calidi Biotherapeutics from $45.00 to $20.00 and set an “outperform” rating for the company in a research report on Wednesday, May 15th. LADENBURG THALM/SH SH assumed coverage on Calidi Biotherapeutics in a report on Thursday, June 27th. They issued a “buy” rating and a $10.00 target price for the company.
About Calidi Biotherapeutics
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer with a novel stem cell-based therapy. Calidi Biotherapeutics Inc, formerly known as First Light Acquisition Group, is based in SAN DIEGO.
See Also
- Five stocks we like better than Calidi Biotherapeutics
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Serve Robotics Is Serving Up a Selling Opportunity
- What Is WallStreetBets and What Stocks Are They Targeting?
- Defying the Market: 3 Mega-Cap Stocks Soaring to New Highs
- Why Invest in High-Yield Dividend Stocks?
- Microsoft Stock: Is Now The Time To Be Greedy?
Receive News & Ratings for Calidi Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calidi Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
